Claims:

1. Use of an oligopeptidic compound comprising the amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence having at least 90 % sequence identity thereto, for the manufacture of a medicament for treatment of cancer, wherein said oligopeptidic compound has activity in inhibiting the growth and/or viability of cancer cells and in said treatment said oligopeptidic compound is to be administered to a subject in combination with a checkpoint inhibitor, said checkpoint inhibitor being an antibody which binds PD-1 or PD-L1 and blocks the interaction between PD-1 and PD-L1.

2. The use according to claim 1, wherein said oligopeptidic compound comprises an amino acid sequence having at least 95 % sequence identity to SEQ ID NO: 1.

3. The use according to claim 1 or claim 2, wherein said oligopeptidic compound comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1.

4. The use according to any one of claims 1 to 3, wherein said oligopeptidic compound is an inverso-compound, every amino acid of which is a D-amino acid.

5. The use according to any one of claims 1 to 4, wherein said oligopeptidic compound is selectively cytotoxic towards cancer cells.

6. The use according to any one of claims 1 to 5, wherein the antibody is nivolumab, pembrolizumab, atezolizumab, durvalumab, tislelizumab or avelumab.

7. The use according to any one of claims 1 to 6, wherein said oligopeptidic compound and said checkpoint inhibitor are to be separately, simultaneously or sequentially administered to said subject.

8. The use according to any one of claims 1 to 7, wherein said subject is a mammal.

9. The use according to claim 8, wherein said subject is a human.

10. The use according to any one of claims 1 to 9, wherein said cancer is cervical cancer, anal cancer, vaginal cancer, vulvar cancer, penile cancer, melanoma, lung cancer, a head and neck cancer, bladder cancer, kidney cancer, Hodgkin’s lymphoma, a squamous cell carcinoma or Merkel cell carcinoma.

11. The for use according to any one of claims 1 to 10, wherein said cancer is microsatellite instability-high or mismatch-repair deficient.

12. The use according to any one of claims 1 to 11, wherein said subject is HPV-positive.

13. Use of a checkpoint inhibitor and an oligopeptidic compound in the manufacture of a medicament for treating cancer in a subject, wherein said oligopeptidic compound, checkpoint inhibitor, subject, treatment and cancer are as defined in any one of claims 1 to 12.